Lithium is not a standard treatment for alcohol withdrawal. It is FDA-approved only for bipolar I disorder, and no major clinical guideline recommends it for managing the acute symptoms of alcohol withdrawal. Benzodiazepines remain the first-line approach for that purpose. However, lithium has been studied in this context, and there are specific reasons it attracted interest and specific reasons it never gained traction.
Why Lithium Was Studied for Withdrawal
Alcohol withdrawal happens when the brain, accustomed to alcohol’s calming effects, suddenly loses that input and becomes overexcited. At the neurochemical level, this involves a surge in excitatory signaling (glutamate) and a drop in inhibitory signaling (GABA). Lithium influences both of these systems. It raises GABA levels in certain brain regions and lowers glutamate concentrations, which on paper makes it look like it could dampen the hyperexcitable state that defines withdrawal.
Researchers in the late 1970s tested this idea directly. In a small study of 18 men going through mild alcohol withdrawal, lithium carbonate taken three times daily reduced subjective withdrawal symptoms and improved performance on a motor coordination task. But it did not meaningfully change blood pressure, heart rate, tremor, or sleep patterns during the withdrawal period. The benefits were modest and limited to milder cases.
What the Relapse Research Found
A separate line of research looked at whether lithium could help people stay sober after withdrawal was over. A double-blind, placebo-controlled trial found that among patients who took lithium consistently and reached therapeutic blood levels, 67% remained abstinent. That compared to 31% to 44% abstinence among those who took it but never reached adequate levels, and near-zero abstinence among those who didn’t take the medication reliably.
The researchers noted that patients who began lithium while still hospitalized were significantly less likely to relapse during the first month compared to those on placebo. They concluded the effect appeared to go beyond simple compliance, suggesting lithium had some genuine influence on drinking behavior independent of mood stabilization. Still, the sample size was small, and no large-scale trial has replicated these findings convincingly enough to change clinical practice.
Why It Fell Out of Favor
The core problem is safety. Lithium has one of the narrowest therapeutic windows of any psychiatric medication, meaning the difference between an effective dose and a toxic one is small. The kidneys handle 95% of lithium excretion, and they treat lithium and sodium almost identically. When sodium levels drop, the kidneys hold onto more lithium, pushing blood levels toward toxicity.
This is especially dangerous during alcohol withdrawal. People in withdrawal are frequently dehydrated, vomiting, sweating heavily, and eating poorly. All of these deplete sodium and fluid volume, which directly increases the risk of lithium accumulating to dangerous levels. Even mild dehydration can tip the balance. Chronic lithium use can also impair the kidneys’ ability to concentrate urine, creating a vicious cycle: the kidneys lose their ability to manage fluid balance, which further raises lithium levels, which further damages kidney function.
People with a history of heavy alcohol use often already have compromised liver and kidney function, making them even more vulnerable. Lithium toxicity can cause confusion, seizures, kidney failure, and cardiac problems. In a patient population already at risk for seizures from withdrawal itself, adding that layer of danger is hard to justify when safer alternatives exist.
What Is Used Instead
Benzodiazepines are the standard treatment for acute alcohol withdrawal because they work on the same brain receptors that alcohol does, effectively smoothing the transition as the brain readjusts. They reduce the risk of seizures, ease anxiety and agitation, and have decades of evidence supporting their use in this setting.
For longer-term relapse prevention, three medications have more established track records than lithium: one reduces cravings by stabilizing glutamate signaling, another blocks the pleasurable effects of alcohol, and a third causes an unpleasant physical reaction if you drink. None is perfect, but all have larger evidence bases and more predictable safety profiles than lithium in this population.
Lithium’s Narrow Role Today
The one scenario where lithium might appear in the treatment of someone with alcohol problems is when that person also has bipolar disorder. The overlap between bipolar disorder and alcohol use disorder is substantial, and lithium remains a cornerstone of bipolar treatment. In those cases, lithium is being prescribed for the mood disorder, not for the alcohol withdrawal itself. Clinicians managing these patients need to monitor kidney function and blood lithium levels closely, with blood draws taken 12 hours after the evening dose and repeated every few days when starting treatment, then every three to six months once levels are stable.
Outside of that dual-diagnosis scenario, lithium has no current role in treating alcohol withdrawal. The early research was intriguing but never produced the kind of large, replicated results that would justify using a medication this difficult to manage safely in patients this medically fragile.